Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.54 |
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.49 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6628829 | 0.97 | HTR2C (0.54) | HTR2CPARP1MAPK10RIPK1MAPKAPK2 | |
| SCHEMBL4525164 | 0.80 | MAPKAPK2 (0.53) | HTR2CPARP1MAPK10RIPK1MAPKAPK2 | |
| SCHEMBL28549389 | 0.78 | SMN1; SMN2 (0.50) | PARP1ACHEEGFRALDH1A1KDM4E | |
| SCHEMBL28559488 | 0.78 | SMN1; SMN2 (0.50) | PARP1ACHEEGFRALDH1A1KDM4E | |
| SCHEMBL13711871 | 0.78 | KDM4E (0.57) | HTR2CMAPK10RIPK1KDM4EADRA1A | |
| SCHEMBL4114928 | 0.78 | HTR2C (0.48) | HTR2CPARP1MAPK10RIPK1MAPKAPK2 | |
| SCHEMBL24408232 | 0.77 | NR2E1 (0.56) | HTR2CMAPK10RIPK1MAPKAPK2ADRA1A | |
| SCHEMBL31336631 | 0.77 | ALDH1A1 (0.47) | PARP1EGFRALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL11838861 | 0.77 | ALDH1A1 (0.47) | PARP1EGFRALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL26836954 | 0.77 | MAPKAPK2 (0.56) | HTR2CPARP1MAPK10RIPK1MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1802300-A4 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO INC (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080097108-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2008-04-24 | — | — | US | disclosed |
| US-20080097108-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2008-04-24 | — | — | US | disclosed |
| US-20080097108-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2008-04-24 | — | — | US | disclosed |
| EP-1802300-A1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006044232-A1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080097108-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | KCNH2, KCNN1, KCNH3 | HTR2C 3188/4885PARP1 2634/4885MAPK10 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.